Mont-Saint-Guibert (Belgium), October 9, 2024, 10:35 pm CET / 4:35 pm ET – In accordance with article 15 of the Law of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels and Nasdaq: NYXH) publishes the below information following the issue of new shares.
Contact:
Nyxoah
Loic Moreau, CFO
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$7.86 |
Daily Change: | 0.09 1.16 |
Daily Volume: | 58,412 |
Market Cap: | US$294.200M |
March 26, 2025 March 13, 2025 |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORERecursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MOREEnd of content
No more pages to load